These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 36038616)

  • 41. Sacituzumab govitecan: antibody-drug conjugate in triple-negative breast cancer and other solid tumors.
    Fenn KM; Kalinsky K
    Drugs Today (Barc); 2019 Sep; 55(9):575-585. PubMed ID: 31584574
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cost-effectiveness of Sacituzumab Govitecan versus Single-agent Chemotherapy for Patients with Metastatic Triple-Negative Breast Cancer in China.
    Wang L; Liu L; Zhang Z; Li F; Ruan Y; He Y; Huang J; Zheng X
    Clin Breast Cancer; 2024 Oct; 24(7):e545-e553.e6. PubMed ID: 38760263
    [TBL] [Abstract][Full Text] [Related]  

  • 43. An integrated analysis of Sacituzumab govitecan in relapsed or refractory metastatic triple-negative breast cancer.
    Cheng SX; Chen QC; Lin GH; Han YH; Wang BC; Dai Y; Zhao YX
    Medicine (Baltimore); 2023 Jul; 102(30):e34486. PubMed ID: 37505137
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Role of sacituzumab govitecan in solid tumors.
    Veeraballi S; Khawar Z; Aslam HM; Muzaffar M
    J Oncol Pharm Pract; 2022 Oct; 28(7):1617-1623. PubMed ID: 35404158
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Case report of sacituzumab govitecan-hziy-induced neutropenia in a patient with metastatic triple-negative breast cancer and a uridine diphosphate glucuronosyltransferase family 1 member A1 poor metabolizer genotype.
    Baek G; Jung L; Duong A; Gralow J
    J Oncol Pharm Pract; 2022 Apr; 28(3):710-716. PubMed ID: 34761708
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Sacituzumab for the treatment of triple-negative breast cancer: the poster child of future therapy?
    Zangardi ML; Spring LM; Nagayama A; Bardia A
    Expert Opin Investig Drugs; 2019 Feb; 28(2):107-112. PubMed ID: 30507322
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Economic Evaluation of Sacituzumab Govitecan for the Treatment of Metastatic Triple-Negative Breast Cancer in China and the US.
    Chen J; Han M; Liu A; Shi B
    Front Oncol; 2021; 11():734594. PubMed ID: 34778047
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: results from the NeoSTAR trial.
    Spring LM; Tolaney SM; Fell G; Bossuyt V; Abelman RO; Wu B; Maheswaran S; Trippa L; Comander A; Mulvey T; McLaughlin S; Ryan P; Ryan L; Abraham E; Rosenstock A; Garrido-Castro AC; Lynce F; Moy B; Isakoff SJ; Tung N; Mittendorf EA; Ellisen LW; Bardia A
    Ann Oncol; 2024 Mar; 35(3):293-301. PubMed ID: 38092228
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Neutropenic Enterocolitis: A Rare Complication of Sacituzumab Govitecan.
    Prescott AE; Ravindra A; Javed A
    Case Rep Oncol; 2022; 15(2):687-693. PubMed ID: 36157703
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Managing adverse events of sacituzumab govitecan.
    Schlam I; Tarantino P; Tolaney SM
    Expert Opin Biol Ther; 2023; 23(11):1103-1111. PubMed ID: 37800595
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A comparison of toxicity and health care resource use between eribulin, capecitabine, gemcitabine, and vinorelbine in patients with metastatic breast cancer treated in a community oncology setting.
    Dranitsaris G; Beegle N; Kalberer T; Blau S; Cox D; Faria C
    J Oncol Pharm Pract; 2015 Jun; 21(3):170-7. PubMed ID: 24620009
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sacituzumab govitecan for hormone receptor-positive and triple-negative breast cancers.
    Satti SA; Sheikh MS
    Mol Cell Pharmacol; 2023; 15(1):1-5. PubMed ID: 37090944
    [TBL] [Abstract][Full Text] [Related]  

  • 53. FDA Approval Summary: Accelerated Approval of Sacituzumab Govitecan-hziy for Third-line Treatment of Metastatic Triple-negative Breast Cancer.
    Wahby S; Fashoyin-Aje L; Osgood CL; Cheng J; Fiero MH; Zhang L; Tang S; Hamed SS; Song P; Charlab R; Dorff SE; Ricks TK; Barnett-Ringgold K; Dinin J; Goldberg KB; Theoret MR; Pazdur R; Amiri-Kordestani L; Beaver JA
    Clin Cancer Res; 2021 Apr; 27(7):1850-1854. PubMed ID: 33168656
    [TBL] [Abstract][Full Text] [Related]  

  • 54. First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors.
    Starodub AN; Ocean AJ; Shah MA; Guarino MJ; Picozzi VJ; Vahdat LT; Thomas SS; Govindan SV; Maliakal PP; Wegener WA; Hamburger SA; Sharkey RM; Goldenberg DM
    Clin Cancer Res; 2015 Sep; 21(17):3870-8. PubMed ID: 25944802
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Predictive biomarkers for sacituzumab govitecan efficacy in Trop-2-expressing triple-negative breast cancer.
    Cardillo TM; Rossi DL; Zalath MB; Liu D; Arrojo R; Sharkey RM; Chang CH; Goldenberg DM
    Oncotarget; 2020 Oct; 11(43):3849-3862. PubMed ID: 33196706
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cost-utility analysis of sacituzumab govitecan versus chemotherapy for the treatment of metastatic triple-negative breast cancer in Singapore.
    Cher BP; Goh S; Aziz MIA; Wong G; Ng Chee Hui R; Ong BS; Ng KH
    Expert Rev Pharmacoecon Outcomes Res; 2024 Feb; 24(2):217-225. PubMed ID: 38149409
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cost-effectiveness of sacituzumab govitecan versus chemotherapy in advanced or metastatic triple-negative breast cancer.
    Lang Y; Chai Q; Tao W; Liao Y; Liu X; Wu B
    Breast; 2023 Apr; 68():173-180. PubMed ID: 36780838
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Sacituzumab Govitecan: First Approval.
    Syed YY
    Drugs; 2020 Jul; 80(10):1019-1025. PubMed ID: 32529410
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: A case study of anti-TROP-2 sacituzumab govitecan.
    Goldenberg DM; Sharkey RM
    MAbs; 2019; 11(6):987-995. PubMed ID: 31208270
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A New Kid on the Block: Sacituzumab Govitecan for the Treatment of Breast Cancer and Other Solid Tumors.
    Pavone G; Motta L; Martorana F; Motta G; Vigneri P
    Molecules; 2021 Dec; 26(23):. PubMed ID: 34885875
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.